{"filings":[{"id":3292517,"accession_number":"0001171843-26-006465","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K","filed_at":"2026-10-06T20:30:15+00:00","items":["2.01","9.01"],"status":"ready","headline":"BeyondSpring closes sale of BeyondSpring Ltd. to Biolin for DUBLIN-4 data rights, $53.7M pro forma gain","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed Sept. 30, 2026 sale of all BeyondSpring Ltd. shares, which indirectly held Bulin and SEED Technology, to Biolin Investment Limited; no cash consideration was paid.","Consideration is noncash: Investor funds China portion of DUBLIN-4 Phase 3 trial of Plinabulin plus docetaxel in NSCLC; BYSI gets exclusive perpetual royalty-free license to Bulin Data.","Clawback: if Bulin misses Target Enrollment within three years, Investor returns equity based on shortfall, including 100% of equity if shortfall is 90% or greater.","Pro forma preliminary gain on Sale $53.7M; accumulated deficit improves to $(358.5)M from $(411.4)M, and total shareholders' deficit turns positive at $17.3M.","Deconsolidates BeyondSpring Ltd. and SEED disposal groups; retains ~29% of SEED voting power via common and Series A-1 preferred, with right to elect two directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3236087,"accession_number":"0001171843-26-006371","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K","filed_at":"2026-10-02T20:30:15+00:00","items":["3.01"],"status":"ready","headline":"BeyondSpring gets Nasdaq notice as MVLS falls below $35M; 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Listing Qualifications notified BeyondSpring on September 29, 2026 that market value of listed securities fell below $35 million for 30 consecutive business days, violating Rule 5550(b)(2).","Company has until March 29, 2027 (180 calendar days) to regain compliance; shares continue trading on the Nasdaq Capital Market in the interim.","Compliance is regained if MVLS closes at $35M or more for 10 consecutive business days; Nasdaq staff may extend under Rule 5810(c)(3)(H).","Notification has no immediate effect on listing or business operations; BeyondSpring says it is considering all available options and gives no assurance it will regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3135197,"accession_number":"0001171843-26-006273","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K","filed_at":"2026-09-29T11:03:38+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"BeyondSpring wins FDA Fast Track for Plinabulin in post-ICI NSCLC; sells China unit to fund DUBLIN-4","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["FDA granted Fast Track designation to Plinabulin plus docetaxel for 2L/3L advanced non-squamous NSCLC without actionable genomic alterations, post-ICI and platinum chemo.","DUBLIN-4 Phase 3: ~442 patients randomized 1:1, overall survival primary endpoint with PFS and ORR secondary; prespecified interim analysis at 221 PFS events.","BeyondSpring will sell BeyondSpring Ltd, which indirectly holds its majority stake in Dalian Wanchunbulin (Bulin), to Biolin Investment for no cash; Biolin funds the China portion of DUBLIN-4.","If Bulin misses Target Enrollment within 3 years after closing and the shortfall is 90% or more, Biolin must return 100% of the Equity Interests to BeyondSpring.","ATM program with Citizens JMP Securities covers up to 9,200,000 ordinary shares; agent commission up to 3.0% of gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2962403,"accession_number":"0001171843-26-006116","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K","filed_at":"2026-09-18T20:30:17+00:00","items":["3.01"],"status":"ready","headline":"BeyondSpring receives Nasdaq bid-price delisting notice; 180-day cure window to March 16, 2027","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified BYSI on Sept 17, 2026 that bid price closed below $1.00 for 30 consecutive business days.","Company has until March 16, 2027 to regain compliance by closing at >= $1.00 for 10 straight business days.","No immediate delisting; shares continue trading while company evaluates options to regain compliance.","If not cured by deadline, BYSI may qualify for an additional 180-day compliance period at Nasdaq's discretion.","Company cautions no assurance it will regain compliance or remain listed; business operations unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2273678,"accession_number":"0001171843-26-005557","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K","filed_at":"2026-08-14T21:15:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"BeyondSpring Q2 net loss $1.8M; ASCO data show 58% 24-month OS in post-ICI NSCLC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 net loss $1.8M vs $1.9M YoY; cash and short-term investments $6.5M at June 30, 2026.","ASCO 2026 Phase 2 (n=47): median PFS 7.0 mo, ORR 18.2%, DCR 79.5%, 24-month OS 58.0%.","Leadership effective July 1, 2026: Min Qiu CEO, Jen Majeti Vice Chairman, Na Li CFO.","DUBLIN-4 planned confirmatory Phase 3: 442 patients, non-squamous EGFR-wild-type NSCLC post-ICI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1334124,"accession_number":"0001171843-26-004354","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K/A","filed_at":"2026-06-29T20:30:17+00:00","items":["5.02","9.01"],"status":"ready","headline":"BeyondSpring finalizes CEO Min Qiu compensation: $100K salary, 100K share options, severance terms","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Min Qiu receives $100K salary with 30% target bonus.","Granted options to purchase 100,000 ordinary shares vesting over 4 years.","Severance: 9 months base salary plus pro-rated bonus on termination without cause or for good reason.","CFO Na Li's compensation remains unchanged in connection with her appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":843159,"accession_number":"0001171843-26-003908","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K","filed_at":"2026-06-04T11:30:18+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"BeyondSpring CEO Lan Huang transitions to Chairman; Min Qiu named CEO effective July 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Lan Huang steps down as CEO effective July 1, 2026; remains Chairman; forfeits all unvested equity awards.","Min Qiu appointed CEO; previously VP General Manager at subsidiary Wanchunbulin; mandate to execute DUBLIN-4 Phase 3 trial.","Na Li appointed CFO; previously CFO of Wanchunbulin since Nov 2020; brings public-company financial reporting experience.","Dr. Jiangwen Majeti appointed Vice Chair of Board; receives one-time grant of options for 100,000 ordinary shares.","BeyondSpring focuses on Plinabulin DUBLIN-4 confirmatory trial; patent protection extends to 2036 (potentially 2041 with Hatch-Waxman)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":49927,"accession_number":"0001171843-26-003344","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K","filed_at":"2026-05-13T11:00:21+00:00","items":["2.02","9.01"],"status":"ready","headline":"BeyondSpring Q1 net loss $2.4M from continuing ops; cash $7.9M; AACR data supports Plinabulin-ADC combo","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing operations $2.4M vs $2.6M YoY; discontinued ops loss $4.3M.","Cash and short-term investments $7.9M as of March 31, 2026.","AACR 2026 data: Plinabulin enhances efficacy/tolerability of topoisomerase inhibitor–based ADC regimens.","ST-01156 (RBM39 degrader) advanced to Phase 1; first dose cohort completed.","SEED's operations reported as discontinued due to planned sale of preferred shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107139,"accession_number":"0001171843-26-001890","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BeyondSpring reports FY2025 net loss $8.7M; Plinabulin Phase 3 survival benefit confirmed, DUBLIN-4 planned","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["R&D expense $4.4M, G&A $4.6M; cash $12.6M as of Dec 31, 2025.","Plinabulin+docetaxel achieved OS HR 0.72 in non-squamous NSCLC; DUBLIN-4 confirmatory trial planned.","SEED Therapeutics dosed first patient in Phase 1a for ST-01156; completed $30M Series A-3 financing.","Sold portion of SEED preferred shares for ~$35.4M gross proceeds; first closing $7.35M in Feb 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123479,"accession_number":"0001171843-25-007943","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BeyondSpring delays second closings of SEED Therapeutics share sale to H1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second closings under Preferred Share Purchase Agreement for SEED Therapeutics Series A-1 shares postponed from Dec 2025 to H1 2026.","Three investors (Winning View, FULL TECH, Mapfil) to purchase 3,103,055 shares for ~$13.2M at $4.25/share, now expected H1 2026.","Total deal value for all 8,333,637 shares is $35.4M; no assurance that second closings will not be further delayed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123478,"accession_number":"0001171843-25-007497","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BeyondSpring raises $2.0M via registered direct offering of 800K shares at $2.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 800,000 ordinary shares to Ray Beauty Group Limited at $2.50/share, gross proceeds $2.0M.","Shares offered under existing effective shelf registration statement; closing occurred November 21, 2025.","Investor agreed to a 60-day lock-up from closing, prohibiting sales or hedging of the shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123477,"accession_number":"0001171843-25-007217","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BeyondSpring Q3 2025 net loss $1.7M; Plinabulin DCR 85% in NSCLC post-PD-1/L1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $1.7M vs $2.2M YoY; cash $12.5M up from $2.9M Dec 2024.","Plinabulin + docetaxel + Keytruda in NSCLC: DCR 85%, median PFS 7.0 mo, 12-mo OS 79%.","SEED (38% owned) closed $30M Series A-3, FDA/NMPA IND clearance for RBM39 degrader.","R&D $1.0M, G&A $0.8M; headcount reductions drove lower admin expenses.","Discontinued ops (SEED sale accounting) net loss $3.2M in Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140151,"accession_number":"0001171843-25-006027","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"SEED Therapeutics closes $30M Series A-3, FDA clears IND for lead RBM39 degrader","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Second close of $6M completes $30M Series A-3; BeyondSpring to own ~38.03% on as-converted basis.","FDA cleared IND for ST-01156 (RBM39); first-in-human trial expected Q1 2026.","SEED has received ~$60M in equity and payments from Eli Lilly and Eisai partnerships.","BeyondSpring expects to continue consolidating SEED as it retains substantive control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140150,"accession_number":"0001171843-25-005922","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BeyondSpring shareholders ratify CBIZ CPAs as auditor for FY2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders ratified appointment of CBIZ CPAs P.C. as independent auditor for fiscal year ending Dec 31, 2025.","Vote: 21,831,390 for, 14,265 against, 6,610 abstain; no broker non-votes.","Quorum of 21,852,265 shares (54.19% of outstanding) was present at the September 15, 2025 annual meeting.","No other matters were voted on at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140149,"accession_number":"0001171843-25-005355","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q2 net loss narrows to $1.9M; Plinabulin shows 23% ORR in ICI-refractory cancers","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing operations $1.9M for Q2 2025 vs $2.7M in Q2 2024; cash $9.5M as of Jun 30, 2025 vs $2.9M Dec 2024.","R&D expenses $1.0M; G&A $0.9M, down from $1.8M on lower headcount and professional costs.","Plinabulin combo in PD-1/L1 progressed NSCLC showed median PFS 6.8 mo, ORR 18.2%, DCR 77%, OS 78% at 15 mo.","SEED Therapeutics' RBM39 degrader ST-01156 cleared FDA IND; Dr. Bill Desmarais appointed CFO and CBO.","Discontinued operations loss $2.8M vs $1.4M YoY, reflecting SEED reporting change."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140148,"accession_number":"0001171843-25-004306","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BeyondSpring sets annual meeting for September 15, 2025; record date July 25","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2025 annual meeting of shareholders scheduled for September 15, 2025.","Record date for the meeting is close of business on July 25, 2025.","Shareholder proposals under Rule 14a-8 must be received by July 14, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157797,"accession_number":"0001171843-25-003087","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BeyondSpring Q1 net loss from continuing ops $2.6M; Plinabulin data show promise in PD-1 resistant cancers","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $2.6M, up 24% YoY; R&D expense $0.9M, G&A $1.7M.","Plinabulin combinations showed durable responses in metastatic NSCLC and Hodgkin lymphoma failing PD-1/L1 inhibitors.","SEED's RBM39 degrader achieved complete tumor regression in Ewing sarcoma models; IND filing on track for mid-2025.","SEED reported as discontinued ops after Jan 2025 sale of Series A-1 shares; BeyondSpring retains ~40% stake.","Phase 1 trial of Plinabulin + PD-1 inhibitor + radiation at MD Anderson showed >19-month duration in heavily pretreated Hodgkin lymphoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157796,"accession_number":"0001171843-25-002158","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"BeyondSpring replaces Marcum with CBIZ as auditor after Marcum's resignation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Marcum LLP resigned as independent auditor on April 8, 2025; CBIZ CPAs P.C. engaged April 9, 2025.","No disagreements or reportable events occurred during audits for fiscal years 2024 and 2023.","Marcum's audit reports for 2024 and 2023 were unqualified except for a going-concern explanatory paragraph in 2023.","CBIZ acquired Marcum's attest business on Nov 1, 2024; partners and staff transitioned.","Change approved by Audit Committee; no prior consultations with CBIZ on accounting matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176171,"accession_number":"0001171843-25-001757","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BeyondSpring FY2024 net loss $8.9M; Plinabulin Phase 3 shows OS benefit in NSCLC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $8.9M vs $14.0M in 2023; R&D expenses fell to $2.6M from $7.3M.","Plinabulin Phase 3 data published in Lancet Respiratory Medicine: statistically significant overall survival benefit in 2L/3L NSCLC EGFR wild-type vs docetaxel.","Agreement to sell portion of SEED shares for ~$35.4M gross proceeds; first close of $7.35M in Feb 2025.","SEED entered Eisai research collaboration with potential payments up to $1.5B; completed $24M Series A-3 first close led by Eisai.","SEED's RBM39 degrader ST-01156 granted Rare Pediatric Disease and Orphan Drug Designations by FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176170,"accession_number":"0001171843-25-001050","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"BeyondSpring closes first tranche of SEED Therapeutics stake sale for $7.4M; total deal $35.4M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["First closing transferred 1,730,454 SEED Series A-1 Preferred Shares for $7,354,433 cash.","Amendment added 230,400 shares to Winning View for $979,203; total purchase price unchanged at ~$35.4M.","BYSI ownership in SEED fell from 46.87% to 40.12%; control retained until second closing expected by Dec 2025.","Pro forma gain on disposition of SEED estimated at $67.5M; SEED classified as discontinued operations.","Remaining 6,603,183 shares to be sold in two closings through 2026; no assurance of completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176169,"accession_number":"0001171843-25-000457","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"BeyondSpring sells SEED Therapeutics stake for $35.4M to fund Plinabulin trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sells 8,333,637 Series A-1 Preferred Shares at $4.25/share to three investors for ~$35.4M gross proceeds.","After all closings, BeyondSpring and subsidiary will own ~14.4% of SEED (down from ~41% initially).","Proceeds advance Plinabulin to registrational studies; DUBLIN-3 showed OS benefit in NSCLC.","303 study of Plinabulin + pembrolizumab/docetaxel achieved 89.3% DCR and 8.6 mo median PFS.","302 study enrolling first-line ES-SCLC patients; Plinabulin has GEF-H1 immune activation mechanism."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176168,"accession_number":"0001171843-25-000025","cik":1677940,"company_name":"BeyondSpring Inc.","ticker":"BYSI","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"BeyondSpring changes SEC filing status to domestic issuer as of Jan 1, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective Jan 1, 2025, BeyondSpring no longer qualifies as a foreign private issuer and will file domestic issuer forms.","Domestic issuer filings are more detailed and extensive and must be filed more promptly than foreign private issuer forms.","Company lists official disclosure channels: SEC filings, press releases, website, LinkedIn, and X (Twitter)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":71342888.5116959,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}